



XIV EUROPEAN PATIENTS' RIGHTS DAY

**ONE health approach, MULTIPLE answers:  
Citizens' engagement & stakeholders' actions to tackle antimicrobial resistance  
and sustain EU progress**

DIGITAL CONFERENCE  
18<sup>th</sup> & 19<sup>th</sup> November 2020

# REDUCING HEALTHCARE- ASSOCIATED INFECTIONS INCIDENCE BY A PROBIOTIC-BASED SANITATION SYSTEM: A MULTICENTRE, PROSPECTIVE, INTERVENTION STUDY


Luca Arnoldo

# Introduction


1. Air pollution and climate change
2. Non communicable diseases (NCDs)
3. Global influenza pandemic
4. Fragile and vulnerable settings
5. **Antimicrobial resistance**
6. Ebola and other high-threat pathogens
7. Weak primary healthcare
8. Vaccine hesitancy
9. Dengue
10. HIV




**Figure 4. *Klebsiella pneumoniae*.** Percentage of invasive isolates resistant to third-generation cephalosporins (cefotaxime or/and ceftriaxone or/and ceftazidime), by country, EU/EEA, 2019




**Figure 5. *Klebsiella pneumoniae*.** Percentage of invasive isolates resistant to carbapenems (imipenem or/and meropenem), by country, EU/EEA, 2019




**Figure 6. *Pseudomonas aeruginosa*.** Percentage of invasive isolates with resistance to carbapenems (imipenem or/and meropenem), by country, EU/EEA, 2019




**Figure 8. *Staphylococcus aureus*.** Percentage of invasive isolates resistant to methicillin (MRSA), by country, EU/EEA, 2019




**Figure 10. *Enterococcus faecium*.** Percentage of invasive isolates resistant to vancomycin, by country, EU/EEA, 2019




**Figure 7. *Acinetobacter* species.** Percentage of invasive isolates with resistance to carbapenems (imipenem or/and meropenem), by country, EU/EEA, 2019



**Figure 1. *Escherichia coli*.** Percentage of invasive isolates resistant to fluoroquinolones (ciprofloxacin or/and levofloxacin or/and ofloxacin), by country, EU/EEA, 2019



**Figure 2. *Escherichia coli*.** Percentage of invasive isolates resistant to third-generation cephalosporins (cefotaxime or/and ceftriaxone or/and ceftazidime), by country, EU/EEA, 2019







Fig. 1. Pillars of the South African antimicrobial stewardship strategy framework.<sup>[6]</sup> (IPC = infection prevention and control.)

# Preventing infections



# Aim

- Evaluate the impact of environmental cleanliness through the Probiotic Cleaning Hygiene System (PCHS) on the incidence of healthcare-associated infections (HAIs) in acute care settings
- Probiotic Cleaning Hygiene System (PCHS)
  - Ecosustainable detergent containing spores of *Bacillus spp.* – non pathogens



# Data are available

RESEARCH ARTICLE

## Reducing healthcare-associated infections incidence by a probiotic-based sanitation system: A multicentre, prospective, intervention study


Elisabetta Caselli<sup>1,2\*</sup>, Silvio Brusaferrò<sup>3</sup>, Maddalena Coccagna<sup>2</sup>, Luca Arnoldo<sup>3</sup>, Filippo Berloco<sup>4</sup>, Paola Antonioli<sup>5</sup>, Rosanna Tarricone<sup>6</sup>, Gabriele Pelissero<sup>7</sup>, Silvano Nola<sup>8</sup>, Vincenza La Fauci<sup>9</sup>, Alessandro Conte<sup>3</sup>, Lorenzo Tognon<sup>10</sup>, Giovanni Villone<sup>11</sup>, Nelso Trua<sup>12</sup>, Sante Mazzacane<sup>2</sup>, for the SAN-ICA Study Group<sup>1,2,3,4,5,6,7,8,9,10,11,12†</sup>

PLoS One. 2018 Jul 12;13(7):e0199616



Article

## A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis

Rosanna Tarricone<sup>1,2</sup>, Carla Rognoni<sup>1,\*</sup>, Luca Arnoldo<sup>3</sup>, Sante Mazzacane<sup>4</sup> and Elisabetta Caselli<sup>4,5</sup>

Pathogens 2020 Jun 23;9(6):502

Infection and Drug Resistance

 Open Access Full Text Article

## Impact of a probiotic-based hospital sanitation on antimicrobial resistance and HAI-associated antimicrobial consumption and costs: a multicenter study

Infect Drug Resist. 2019 Feb 27;12:501-510

Dovepress

open access to scientific and medical research

ORIGINAL RESEARCH

# Methods

- Pre-post interventional study
- 5 acute hospitals were included:
  - general medicine, geriatrics and neurological wards;
  - from different part of Italy: 3 in the north, 1 in centre and 1 in south
- Timetable:
  - 6 months of pre-interventional survey:
    - January-June 2016 for three hospitals:  $I_1$
    - May-October 2016 for the other two:  $I_2$
  - Pause period for the PCHS system start-up:
    - 6 months for  $I_1$
    - 2 months for  $I_2$
  - 6 months of survey during PCHS application: January-June 2017 for all the five hospitals
- 1 control hospital especially included for the evaluation of the environmental impact



# Patients characteristics


Table 2. Patient characteristics of the I<sub>1</sub>-I<sub>2</sub> hospitals in the pre-PCHS and PCHS periods (11,461 patients).

Patients characteristics	Pre-PCHS	PCHS
	Total patients No. (%)	Total patients No. (%)
<b>Total</b>	<b>5,930</b>	<b>5,531</b>
<b>Gender: male</b>	2,977 (50.2%)	2,928 (52.9%)
<b>Age &lt;65</b>	1,518 (25.6%)	1,265 (22.9%)
<b>Age 65–74</b>	1,261 (21.3%)	1,177 (21.3%)
<b>Age 75–84</b>	1,821 (30.7%)	1,753 (31.7%)
<b>Age ≥85</b>	1,330 (22.4%)	1,336 (24.2%)
<b>Incontinence</b>	1,448 (24.4%)	1,369 (24.8%)
<b>Disorientation</b>	804 (13.6%)	747 (13.5%)
<b>Self-sufficiency</b>	3,671 (61.9%)	3,632 (65.7%)
<b>Pressure sores</b>	393 (6.6%)	237 (4.3%)
<b>Surgery 30 day before</b>	122 (2.1%)	80 (1.4%)
<b>Ventilation</b>	215 (3.6%)	161 (2.9%)
<b>Parenteral nutrition</b>	200 (3.4%)	141 (2.5%)
<b>ATB 2 week before</b>	566 (9.5%)	294 (5.3%)
<b>MDRO at admission</b>	131 (2.2%)	83 (1.5%)
<b>Infection at admission</b>	1,216 (20.5%)	1,089 (19.7%)
<b>Urinary catheter (any type)</b>	1,368 (23.1%)	1,166 (21.1%)
<b>CVC</b>	264 (4.5%)	260 (4.7%)

Self-sufficiency, ability to provide for themselves autonomously, measured by SSM (Self Sufficiency Matrix) scale; ATB, antibiotics; MDRO, multi drug resistant organism; CVC, central vascular catheter.


Evaluation of sample (sink, floor, bed footboard) for:

- *Staphylococcus spp.*
- *Enterobacteriaceae spp.*
- *Acinetobacter spp.*
- *Mycetes*
- *Pseudomonas spp.*
- *C. difficile*



Interventional hospitals

Control hospital



Interventional hospitals

Control hospital



**Table 1** Variations in individual pathogens' load on hospital surfaces during pre-PCHS and PCHS (CFU/m<sup>2</sup>)

Pathogen type	Pre-PCHS <sup>a</sup>	PCHS <sup>a</sup>	Decrease (%)
<i>Aspergillus</i> spp.	181±307	12±6	93.3
<i>Candida</i> spp.	2,597±1,798	1,108±559	57.3
<i>Clostridium difficile</i>	334±290	132±219	60.5
<i>Pseudomonas aeruginosa</i>	970±982	415±350	57.2
<i>Acinetobacter baumannii</i>	2,844±841	520±726	81.7
<i>Enterobacteriaceae</i> spp.	1,774±901	189±135	89.3
<i>Staphylococcus</i> spp.	26,947±17,293	4,674±3,799	82.7

**Note:** <sup>a</sup>Results are expressed as mean value of CFU/m<sup>2</sup> ± SD detected in the five enrolled hospitals.

**Abbreviations:** PCHS, Probiotic Cleaning Hygiene System; CFU, colony forming units.


# Bacterial resistome



# Comparison of HAI incidence between phases:

- ❑ pre-PCHS (Conventional Chemical Cleaning)
- &
- ❑ PCHS

	All the population N. 11,461			Propensity score matching sample N. 8,320		
	Pre-PCHS	PCHS		Pre-PCHS	PCHS	
Cumulative incidence of patients with at least on HAI	4.8% (284/5,930)	2.3% (128/5,531)	OR 0.47 CI 95% 0.38-0.58	4.6% (191/4,160)	2.4% (100/4,160)	OR 0.47 CI 95% 0.37-0.60
Incidence rate x 1,000 hospitalisation days	5.4 (314/57,742)	2.4 (141/58,201)	OR 0.45 CI 95% 0.36-0.54	5.2 (210/40,111)	2.5 (111/44,751)	OR 0.47 CI 95% 0.38-0.60



# Impact of risk factors on HAI onset

Table 5. Risk factors associated with HAI onset in patients of I<sub>1</sub>-I<sub>2</sub> hospitals: Multivariable model\*.

Population characteristics	<i>P</i>	OR	95% CI
Male	0.01812	0.78	0.63–0.96
Age 65–74 vs Age <65	0.0047	1.71	1.18–2.48
Age 75–84 vs Age <65	0.0004	1.88	1.33–2.67
Age 85 or more vs Age <65	0.0026	1.78	1.22–2.58
Length of stay	<i>p</i> <0.0001	1.08	1.07–1.09
Incontinence	0.2253	0.85	0.66–1.10
Disorientation	0.0226	1.37	1.05–1.76
Self-sufficiency	0.5600	0.92	0.69–1.43
Pressure sores	0.9757	0.99	0.69–1.44
Ventilation	0.7702	1.07	0.68–1.67
ATB 2 week before	0.8479	0.97	0.68–1.37
MDRO at admission	0.6230	0.86	0.47–1.57
Urinary catheter (any type)	<i>p</i> <0.0001	2.68	2.10–3.41
CVC	0.0001	1.99	1.40–2.82
PCHS	<i>p</i> <0.0001	0.44	0.35–0.54

# Conclusions

- Data suggests a positive effect of PCHS application in order to prevent the HAIs onset in the involved wards
- PCHS effect seems to be higher for the HAIs transmitted by contact
- Important to sustain the further researches:
  - other time period
  - different care settings





THE ELECTRIC LIGHT DID NOT  
COME FROM THE CONTINUOUS  
IMPROVEMENT OF CANDLES

(OREN HARARI)